CH642550A5 - Soluzione polisalinica per emodialisi, contenendo una acil-carnitina. - Google Patents
Soluzione polisalinica per emodialisi, contenendo una acil-carnitina. Download PDFInfo
- Publication number
- CH642550A5 CH642550A5 CH448279A CH448279A CH642550A5 CH 642550 A5 CH642550 A5 CH 642550A5 CH 448279 A CH448279 A CH 448279A CH 448279 A CH448279 A CH 448279A CH 642550 A5 CH642550 A5 CH 642550A5
- Authority
- CH
- Switzerland
- Prior art keywords
- carnitine
- ions
- post
- acyl
- hemodialysis
- Prior art date
Links
- 238000001631 haemodialysis Methods 0.000 title claims description 48
- 230000000322 hemodialysis Effects 0.000 title claims description 48
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 title claims description 20
- 150000003839 salts Chemical class 0.000 claims description 9
- -1 isovaleryl Chemical group 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229960001031 glucose Drugs 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 229910001414 potassium ion Inorganic materials 0.000 claims description 3
- 229910001415 sodium ion Inorganic materials 0.000 claims description 3
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 claims description 2
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 45
- 229960004203 carnitine Drugs 0.000 description 26
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 24
- 238000002567 electromyography Methods 0.000 description 21
- 230000035882 stress Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 238000000502 dialysis Methods 0.000 description 19
- 230000000737 periodic effect Effects 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 10
- 208000020832 chronic kidney disease Diseases 0.000 description 10
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 10
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 6
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 6
- 229960001009 acetylcarnitine Drugs 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000004 hemodialysis solution Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT49355/78A IT1156741B (it) | 1978-05-15 | 1978-05-15 | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH642550A5 true CH642550A5 (it) | 1984-04-30 |
Family
ID=11270450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH448279A CH642550A5 (it) | 1978-05-15 | 1979-05-14 | Soluzione polisalinica per emodialisi, contenendo una acil-carnitina. |
| CH448179A CH642549A5 (it) | 1978-05-15 | 1979-05-14 | Soluzione polisalinica per emodialisi, contenendo carnitina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH448179A CH642549A5 (it) | 1978-05-15 | 1979-05-14 | Soluzione polisalinica per emodialisi, contenendo carnitina. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4272549A (https=) |
| JP (2) | JPS54151130A (https=) |
| BE (2) | BE876262A (https=) |
| CA (2) | CA1134274A (https=) |
| CH (2) | CH642550A5 (https=) |
| DE (2) | DE2919543A1 (https=) |
| DK (2) | DK198179A (https=) |
| FR (2) | FR2425855A1 (https=) |
| GB (2) | GB2020552B (https=) |
| IE (2) | IE48122B1 (https=) |
| IL (2) | IL57267A0 (https=) |
| IT (1) | IT1156741B (https=) |
| LU (2) | LU81264A1 (https=) |
| NL (2) | NL7903823A (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| DE2921852A1 (de) * | 1979-05-29 | 1980-12-11 | Fresenius Chem Pharm Ind | Lipide senkendes mittel |
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| JPS5661314A (en) * | 1979-10-24 | 1981-05-26 | Otsuka Pharmaceut Factory Inc | Preventive against side-effect for dialytic patient |
| US4335335A (en) * | 1980-02-11 | 1982-06-15 | Rca Corporation | Television receiver high voltage protection circuit |
| IT1145362B (it) * | 1980-03-06 | 1986-11-05 | Sigma Tau Ind Farmaceuti | Classe di acil-derivati della carnitina procedimento per la loro preparazione e loro uso terapeutico |
| IT1145371B (it) * | 1980-05-30 | 1986-11-05 | Sigma Tau Ind Farmaceuti | Alcossi-acil carnitine procedimento per la loro preparazione e composizioni farmaceutiche che le contengono |
| IT1147079B (it) * | 1980-05-30 | 1986-11-19 | Sigma Tau Ind Farmacuetiche Ri | Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono |
| DE3224823A1 (de) * | 1982-07-02 | 1984-01-05 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer fuer den entsprechenden krankheitsfall optimierten elektrolytloesung zur anwendung in der haemodialyse |
| US4687808A (en) * | 1982-08-12 | 1987-08-18 | Biospecific Technologies, Inc. | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors |
| US4737544A (en) * | 1982-08-12 | 1988-04-12 | Biospecific Technologies, Inc. | Biospecific polymers |
| IT1157238B (it) * | 1982-10-29 | 1987-02-11 | Sigma Tau Ind Farmaceuti | Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile |
| US5719119A (en) * | 1985-12-18 | 1998-02-17 | British Technology Group, Ltd. | Parenteral nutrition therapy with amino acids |
| DE3821043A1 (de) * | 1988-06-22 | 1989-12-28 | Fresenius Ag | Dialysier- und spuel-loesung zur intraperitonealen verabreichung |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| CA2289123A1 (en) | 1997-05-05 | 1998-11-12 | Creative Biomolecules, Inc. | Therapies for acute renal failure |
| JP2001513370A (ja) | 1997-08-07 | 2001-09-04 | グプタ，アジャイ | 水溶性ビタミン及び栄養素を含む透析溶液 |
| KR100461572B1 (ko) * | 1999-03-27 | 2004-12-14 | 삼성정밀화학 주식회사 | Ｌ-카르니틴 칼슘 염과 이의 제조방법 |
| BE1012930A3 (fr) * | 1999-10-08 | 2001-06-05 | Lhoist Rech & Dev Sa | Produit a base d'oxyde de calcium et son procede de fabrication. |
| ATE336243T1 (de) | 1999-10-11 | 2006-09-15 | Sigma Tau Ind Farmaceuti | Verwendung von l-carnitin und seinen alkanoyl- derivaten als osmotisches mittel in lösungen für medizinische verwendung |
| US6914076B2 (en) * | 2000-01-19 | 2005-07-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| US6335369B1 (en) * | 2000-01-19 | 2002-01-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| US6429230B1 (en) * | 2000-01-19 | 2002-08-06 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Treating chronic uremic patients undergoing periodical dialysis |
| EP1257266A1 (en) * | 2000-01-19 | 2002-11-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| JP2006075195A (ja) * | 2004-09-07 | 2006-03-23 | Jms Co Ltd | Ｌカルニチン含有腹膜透析液 |
| US20070087975A1 (en) * | 2005-10-17 | 2007-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
| GR1009311B (el) * | 2017-01-26 | 2018-06-19 | Βερμα Ντραγκς - Verma Drugs Abee | Οξινο κιτρικο διαλυμα αιμοκαθαρσης με l-καρνιτινη |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3822344A (en) * | 1967-04-28 | 1974-07-02 | Cox & Co Ltd A | Pharmaceutical compositions providing potassium chloride in aqueous solution |
| ES356006A1 (es) * | 1967-07-03 | 1969-12-16 | Italseber Sa | Procedimiento para la preparacion de clorhidrato de acetoa-cetilcarnitina dextrogira y levogira. |
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| US3830931A (en) * | 1972-11-06 | 1974-08-20 | Felice S De | Carnitine and its use in the treatment of arrhythmia and impaired cardiac function |
| US3968241A (en) * | 1972-11-06 | 1976-07-06 | Defelice Stephen L | Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof |
| JPS5058213A (https=) * | 1973-09-26 | 1975-05-21 | ||
| AU518617B2 (en) * | 1977-04-29 | 1981-10-08 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutic application of acetyl-d, 1-carnitine |
| JPS53124610A (en) * | 1977-05-17 | 1978-10-31 | Sodekusu:Kk | Dialysate |
| JPS5428809A (en) * | 1977-08-08 | 1979-03-03 | Medekusu Kk | Injection solution for filter type artificial kidney |
| IT1143611B (it) * | 1977-11-03 | 1986-10-22 | Sigma Tau Ind Farmaceuti | Applicazione della acetil-carnitina nella terapia delle affezioni cardiache di/tipo anossico,ischemico,cardiotossico e nelle sindromi aritmiche |
| FR2414914A1 (fr) * | 1978-01-18 | 1979-08-17 | Sigma Tau Ind Farmaceuti | Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine |
| DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
| DE2903558C2 (de) * | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Verwendung von L-Carnitin |
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
-
1978
- 1978-05-15 IT IT49355/78A patent/IT1156741B/it active
-
1979
- 1979-05-14 CH CH448279A patent/CH642550A5/it not_active IP Right Cessation
- 1979-05-14 IL IL57267A patent/IL57267A0/xx not_active IP Right Cessation
- 1979-05-14 DK DK198179A patent/DK198179A/da not_active Application Discontinuation
- 1979-05-14 GB GB7916633A patent/GB2020552B/en not_active Expired
- 1979-05-14 CH CH448179A patent/CH642549A5/it not_active IP Right Cessation
- 1979-05-14 IL IL57265A patent/IL57265A0/xx not_active IP Right Cessation
- 1979-05-14 DK DK198279A patent/DK198279A/da not_active Application Discontinuation
- 1979-05-14 GB GB7916634A patent/GB2020550B/en not_active Expired
- 1979-05-14 FR FR7912197A patent/FR2425855A1/fr active Granted
- 1979-05-14 US US06/038,734 patent/US4272549A/en not_active Expired - Lifetime
- 1979-05-14 FR FR7912196A patent/FR2425854A1/fr active Granted
- 1979-05-15 JP JP6023679A patent/JPS54151130A/ja active Granted
- 1979-05-15 BE BE0/195170A patent/BE876262A/xx not_active IP Right Cessation
- 1979-05-15 CA CA327,599A patent/CA1134274A/en not_active Expired
- 1979-05-15 DE DE19792919543 patent/DE2919543A1/de not_active Withdrawn
- 1979-05-15 LU LU81264A patent/LU81264A1/xx unknown
- 1979-05-15 NL NL7903823A patent/NL7903823A/xx not_active Application Discontinuation
- 1979-05-15 BE BE0/195171A patent/BE876263A/xx not_active IP Right Cessation
- 1979-05-15 NL NL7903824A patent/NL7903824A/xx not_active Application Discontinuation
- 1979-05-15 DE DE19792919593 patent/DE2919593A1/de active Granted
- 1979-05-15 CA CA000327598A patent/CA1135626A/en not_active Expired
- 1979-05-15 JP JP6023779A patent/JPS54151131A/ja active Pending
- 1979-05-15 US US06/039,233 patent/US4237167A/en not_active Expired - Lifetime
- 1979-05-15 LU LU81263A patent/LU81263A1/xx unknown
- 1979-08-08 IE IE952/79A patent/IE48122B1/en not_active IP Right Cessation
- 1979-08-08 IE IE951/79A patent/IE48121B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0530809B2 (https=) | 1993-05-11 |
| FR2425855A1 (fr) | 1979-12-14 |
| JPS54151130A (en) | 1979-11-28 |
| IE790952L (en) | 1979-11-15 |
| IT1156741B (it) | 1987-02-04 |
| CH642549A5 (it) | 1984-04-30 |
| BE876262A (fr) | 1979-09-03 |
| BE876263A (fr) | 1979-09-03 |
| GB2020552B (en) | 1982-10-20 |
| FR2425854A1 (fr) | 1979-12-14 |
| CA1135626A (en) | 1982-11-16 |
| IL57265A0 (en) | 1979-09-30 |
| US4237167A (en) | 1980-12-02 |
| DE2919593C2 (https=) | 1990-12-06 |
| CA1134274A (en) | 1982-10-26 |
| JPS54151131A (en) | 1979-11-28 |
| GB2020550B (en) | 1982-12-15 |
| LU81264A1 (fr) | 1979-09-10 |
| DE2919543A1 (de) | 1979-11-22 |
| IE48121B1 (en) | 1984-10-03 |
| DK198279A (da) | 1979-11-16 |
| NL7903823A (nl) | 1979-11-19 |
| DE2919593A1 (de) | 1979-11-22 |
| IL57267A0 (en) | 1979-09-30 |
| IE48122B1 (en) | 1984-10-03 |
| FR2425855B1 (https=) | 1983-09-16 |
| IT7849355A0 (it) | 1978-05-15 |
| GB2020550A (en) | 1979-11-21 |
| GB2020552A (en) | 1979-11-21 |
| FR2425854B1 (https=) | 1983-08-05 |
| IE790951L (en) | 1979-11-15 |
| LU81263A1 (fr) | 1979-09-10 |
| NL7903824A (nl) | 1979-11-19 |
| US4272549A (en) | 1981-06-09 |
| DK198179A (da) | 1979-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH642550A5 (it) | Soluzione polisalinica per emodialisi, contenendo una acil-carnitina. | |
| Buchanan et al. | Abnormalities of glucagon metabolism in untreated diabetes mellitus | |
| Sebel et al. | Cardiovascular effects of sufentanil anesthesia | |
| Perez et al. | Hyporeninemia and hypoaldosteronism in diabetes mellitus | |
| Takki et al. | Ketamine and plasma catecholamines | |
| DE69432027T2 (de) | Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren | |
| EP0502925A1 (en) | METHOD AND COMPOSITION FOR TREATING INFLAMMABLE INTESTINAL DISEASES. | |
| Kleiman et al. | Left ventricular dynamics during long-term digoxin treatment in patients with stable coronary artery disease | |
| Davis et al. | Dynamic assessment of the electrocardiographic QT interval during citrate infusion in healthy volunteers. | |
| Nishikawa et al. | Asystole during spinal anaesthesia after change from Trendelenburg to horizontal position | |
| Sanchez et al. | Dynamics of serum potassium change during acute respiratory alkalosis | |
| Wang et al. | Cardiac receptor influences on the plasma osmolality-plasma vasopressin relationship | |
| Kurz et al. | Mechanisms of enhanced renin secretion during CO2 retention in dogs | |
| Phillips et al. | Plasma morphine concentrations and clinical effects after thoracic extradural morphine or diamorphine | |
| Casson et al. | Cardiac rate and rhythm during anaesthesia for dental extraction: A comparison of halothane, enflurane and isoflurane | |
| Sandler et al. | Esmolol compared with placebo in preventing increases in heart rate and blood pressure during rigid bronchoscopy | |
| Östman et al. | Influence of isoflurane on renal and intestinal vascular responses to stress | |
| Olgart et al. | Inhibition of compound 48/80‐induced intradental sensory nerve activity by disodium cromoglycate and serotonin antagonists | |
| US5238960A (en) | Use of acetic acid for regulating blood sugar levels | |
| Aromaa et al. | The role of diazepam and fentanyl in the production of balanced anaesthesia | |
| Chiariello et al. | Prajmalium bitartrate in chronic ventricular arrhythmias: comparison with disopyramide | |
| Pholpramool et al. | Modification of in vivo lacrimal gland secretion by 2, 4-dinitrophenol | |
| Purdell-Lewis | Studies of fentanyl-supplemented anaesthesia: Effect of naloxone on the circulation and respiration | |
| Wiersbitzky et al. | The reactions of renal excretory function in normotensive and essentially hypertensive men in response to oral administration of almitrine bismesylate | |
| Roy et al. | Mechanism for inhibition of renin release by acute plasma volume expansion in the dog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |